Document Classification

Section Type: METHODS

Text: Between Dec 1, 2006, and July 4, 2008, patients with untreated HER2-negative metastatic breast cancer were randomly assigned (using a randomisation list created by personnel not associated with the study) in a 1:1:1 ratio to paclitaxel (90 mg/m (2) on days 1, 8, and 15 every 3 weeks) plus either masked motesanib 125 mg orally once per day (n = 91), masked placebo orally once per day (n = 94), or open-label bevacizumab 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle (n = 97), after stratification according to adjuvant or neoadjuvant chemotherapy (taxane-containing regimens vs other regimens vs none), number of metastatic sites (< 3 vs 3), and hormone receptor status (positive vs negative).